Delisting, Listing Rule Failure, or Listing Transfer

Form 8-K Summary

Registrant: Coeptis Therapeutics Holdings, Inc. The request metadata identifies “Z Squared Inc.,” but the filing names Coeptis Therapeutics Holdings, Inc. as the registrant.

Business Context and Reporting Period

This Form 8-K was filed on December 29, 2022, reporting an event dated December 22, 2022. The company is listed on The Nasdaq Global Market under the symbols COEP (common stock) and COEPW (warrants).

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.

Material Change Versus Prior Period

On December 22, 2022, Nasdaq notified the company that its Market Value of Listed Securities had remained below the $50 million continued-listing requirement for 30 consecutive business days under Nasdaq Listing Rule 5450(b)(3)(A).

Listing Compliance, Outlook, and Risks

  • The company received an initial 180-calendar-day compliance period ending June 20, 2023.
  • Compliance may be regained if the company’s MVLS closes at or above $50 million for at least 10 consecutive business days before the deadline.
  • The deficiency letter had no immediate effect on the listing or trading of the company’s securities.
  • If compliance is not restored by June 20, 2023, Nasdaq may notify the company that its securities are subject to delisting.
  • The company may appeal a delisting determination to a Nasdaq hearings panel.
  • Management stated that it would monitor MVLS and consider options including seeking an extension, appealing to a Nasdaq Hearings Panel, or pursuing listing on another Nasdaq tier.

Important Facts for Investors to Verify

  • Whether the company restored compliance with the $50 million MVLS requirement by June 20, 2023.
  • Whether Nasdaq granted an extension or issued a delisting determination.
  • Any subsequent appeal, hearings-panel decision, or transfer to another Nasdaq market tier.
  • The company’s later liquidity, financing, share-price, and market-capitalization position, which are not provided in this filing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.